Novartis Meningitis Vaccine Gets EU Approval

Novartis has won approval by the EU's medicine agency for its Bexsero vaccine against meningitis B infections, say sources. "Bexsero will be the first licensed broad coverage vaccine that can help protect all age groups against MenB (Meningococcal serogroup B) disease, including infants, the age group at the greatest risk of infection," Novartis said in a statement.

Current vaccines offer protection for several types of the disease that causes an inflammation of the membranes covering the brain and spinal cord, but not against MenB, which accounts for up to 90 percent of all cases of the disease in some European countries, the statement added.

Meningitis - Causes - Symptoms - Diagnosis - Treatment - FAQs
Meninges are the three layers of membrane that cover the brain and infection of the cerebrospinal fluid between them causes meningitis the disease of the meninges.

"MenB disease is easily misdiagnosed, can kill within 24 hours and may cause serious, life-long disabilities," Novartis said.

The highest rates of the disease occur the first year of life, peaking by 7 months of age, the statement said.

A final decision on whether the vaccine can be launched throughout the European Union and European Economic Area must be announced within three months by the European Commission, Novartis said, indicating that EU chiefs usually followed the recommendations of the Committee for Medicinal Products for Human Use (CHMP).

Hib Vaccine - Types, Dosage Schedule, Contraindications and Side Effects
The Hib vaccine protects children against infections like meningitis and pneumonia that are caused by the Haemophilus influenzae type b bacterium.

Approximately 1.2 million cases of invasive meningococcal disease are recorded worldwide, and 7,000 occur in Europe, according to the European Medicines Agency (EMA) which approved the vaccine.

Of the 13 meningococcal types, EMA said, in Europe group B is the most prevalent, with 3,406-4,819 cases reported annually between 2003 and 2007.

First to Gain Approval to Travel Outside Cold Chain Is Meningitis Vaccine That Breaks Barrier
Regulatory authorities—after conducting a rigorous review of stability data—will for the first time allow a vaccine in Africa to be transported and stored.

Source-AFP

Novartis Reveals Development of New Meningitis Vaccine for Teens
Leading pharmaceutical giant Novartis revealed that it has developed a new vaccine that provides teenagers with full protection against meningitis B bacteria.